Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WHOEVER THINKS THIS GARBAGE WILL RUN NEEDS TO SEEK SOME HELP
YOU AND YOUR FELLO CLOWN BUDDY MADE COMPLETE FOOLS OF YOURSELVES YET AGAIN...ITS AUGUST DUMMY GOING INTO SEPT OCT...ANYONE WITH HALF A BRAIN KNOWS WHERE WE GO FROM HERE
Oh it's the old pump tard, how's your long trade working out for you in $SPY for the past week😄,not so good I would guess,well I have $560.00 put strikes and doing just fine,you on the other hand deep in the red zone.
HOW CLOWN..WHERE DID YOUR CLOWN BUDDY GO...HIS MARKET CRASH WORKED OUT WELL
SGMO...50...Looks like they want to fill the open gap here...🥳
Your very welcome...🥳
Thanks so much g18 and GLTUA!!! I enjoy reading your charting analysis!!!
Yes...I think $2 plus is coming ...Todays News was very strong...🥳
Hey g18 you think this one has another upward push by your charts ? Thank you so much for any help
The criminal manipulators should be getting squeezed over a buck,today's sellers are clueless.
Don't let the corrupt naked short manipulators get away with their crooked shakeouts, put sell orders over a buck,and let the crooks get their azzes squeezed through the roof.
SGMO: Today's news is just the start of the climb from recent bottom IMO. $3-$5?
SGMO..................................................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783
MMs playing this like a fiddle...back to .45...🥳
SGMO...45s hitting here in the P/M...Off the .33 dip...🥳
While it wasn't many shares, it did hit .45 AH's, with a tiny hit @ .4519.
Finished the AH's @ .43 and on the move up at this moment.
Nice close ...just need it to Break/Hold .42...🥳
SGMO: .40 @ close, now .42 AH's.
SGMO...3912...HOD...Nice candle forming here...🥳Like to see a Break/Hold of .43 range for now...
SGMO: Very good sign, breaking the morning high. (.3889) Especially after all the whacking, following that morning high.😜
SGMO...37s clearing here...🥳
georgie18
Member Level
Re: None
Wednesday, July 10, 2024 9:24:02 AM
Post#
381804
of 381814
SGMO...33...Looks Like a Reversal setting up here... https://schrts.co/fxvIUFMa ...Adding here...🥳
SGMO...33...Looks Like a Reversal setting up here... https://schrts.co/fxvIUFMa ...Adding here...🥳
It always sucks until it doesn't...🥳lets see where she lands...
The PPS sucks for now, but I'm taking chance that some sort of deal, that provides revenue will be reached this quarter. Kind of a All or Nothing type of thing.
I haven't added in weeks, but am bidding in a couple of spots below 30.
Good Luck if you are still holding.
https://www.nasdaq.com/market-activity/stocks/sgmo/analyst-research
Thanks ...market closed yesterday ...lets see what today brings...🥳
SGMO: Looks like we're waiting on a Boom or Bust, no shares traded so far.
Estimated date of Ph. 3 Primary Completion was 06-17-24 and after that drop in PPS recently, which looked like a Short Cover Smackdown, I'm hoping for a move North at any time???
(Concerning the possible Smackdown. That could explain why we have no volume today. Shorts are out? IB's Borrow Rate is .8% today.)
https://clinicaltrials.gov/study/NCT04370054
Also has a lot of room to go up.
For anyone who can read ahead, yesterday's filing was not a shock. Look at the chart below and it will show the market knew it was coming.
But the news that came with it, about future developments actually sent the pps higher today than all week.
Some folks can't figure out why their trades fail. It's timing.
https://www.barchart.com/stocks/quotes/SGMO/interactive-chart
Sangamo Therapeutics traded @ ( $0.2911 ) on ( November 13, 2023 ), this has a massive amount of room to go down ⏬ 🍂🍁 to that level again, especially with the earnings report that came out yesterday ( May 9, 2024 )
Sangamo Therapeutics Flawless Balance ⚖️ Sheet And Extremely Undervalued... Fair Value ( $30.70 ) A Share
Sangamo Therapeutics traded @ ( $0.2911 ) on ( November 13, 2023 ), this has a massive amount of room to go down ⏬ 🍂🍁 to that level again, especially with the earnings report coming out on Monday ( April 29, 2024 )
It would seem so but as each do goes on the faith in sandy to get anything down keeps going down. Really hard to have any faith in that liar.
They should not get a darn penny sandy drove the stock right back into the ground after the run to 1.40. He still cannot get a Farby deal done which is beyond absurd.
So they have chosen to not communicate with their customers as to the issue(s) and timing of a return? If they are closing down the website, then should have the courtesy of letting the paying customers know.
Investor Village site still down it seems. Has anyone heard anything re. a fix?
Thanks, but I don't think that far down the road with a stock who's PPS is at this level.
To me, these stocks are glorified Pinks.
JMO
They have cash until the end of Q3, but if additional funding isn't in place by then (at the latest) it's lights out. Shareholders should consider voting "against" a number of corporate incentives on the table. Officers should not be receiving bonuses this time around.
Looking like the climb back up, is still on track in the new month.
Followers
|
85
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
878
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |